Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL-2)
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Udenafil (Primary)
- Indications Ventricular dysfunction
- Focus Registrational; Therapeutic Use
- Acronyms FUEL-2
- Sponsors Mezzion
Most Recent Events
- 11 Jun 2025 According to a Mezzion media release, company announced a major milestone in their clinical development program, having secured approximately $20 million USD in strategic funding to support the ongoing global Phase 3 FUEL-2 trial of udenafil for patients with Fontan circulation.
- 01 Mar 2024 According to a Mezzion media release, currently, 22 sites in the U.S. are enrolling or will begin enrolling in the coming weeks.
- 01 Mar 2024 According to a Mezzion media release, the company has announced Dr. Rahul Rathod, as the Global Principal Investigator of FUEL-2.He will lead the study analysis and contribute to reporting the results to the Food and Drug Administration (FDA).